ARTICLE | Deals
Along with potential Keytruda competitor, German biotech gains pipeline, bispecific platform, and China sites via acquisition
By Paul Bonanos, Director of Biopharma Intelligence
November 14, 2024 12:00 AM UTC
By buying out China-based partner Biotheus for $800 million up front, BioNTech will receive full global rights to a bispecific antibody that could compete with established blockbuster Keytruda, as well as a pipeline and platform to generate and advance more bispecifics efficiently.
The deal will give BioNTech SE (NASDAQ:BNTX) full control of PD-L1 x VEGF inhibitor BNT327 (PM8002), a clinical bispecific in the same class as ivonescimab from Akeso Inc. (HKEX:9926). BioNTech already held rights to BNT327 outside Greater China under a November 2023 deal…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654180/already-partners-on-bispecific-biontech-buys-biotheus-for-800m